Tehran University of Medical Sciences Basic & Clinical Cancer Research 2228-6527 14 2 2023 08 29 113 122 Soumita Poddar Assistant Professor, Department of Radiotherapy,  Murshidabad Medical college and Hospital.  Amitabha Chakrabarti Associate Professor, Department of Radiotherapy, R.G.Kar Medical College and Hospital, Kolkata. Designation in Murshidabad Medical college and Hospital: Associate Professor. Bodhisattwa Dutta Present Designation: Specialist, Grade 2, Department of Radiation Oncology, Chittaranjan National Cancer Institute, Kolkata. Designation in Murshidabad Medical College and Hospital: Medical Officer (Specialist). Murshidabad Medical college and Hospital. Santu Mondal Department of Radiotherapy, I.P.G.M.E.R and S.S.K.M Hospital, Kolkata, West Bengal SK. MD. Rejakul Islam Residential Medical Officer cum Clinical Tutor, Department of Radiotherapy, Murshidabad Medical college and Hospital. Azizul Purkait RMO cum Clinical Tutor, Department Radiotherapy, Murshidabad Medical college and Hospital. 2023 01 23 2023 02 21 Background:       Carcinoma  breast  is  most  commonly  diagnosed  cancer  at  present. Due  to  systemic  nature  of  disease,  chemotherapy  plays  an  important  role  in  treatment  of  carcinoma breast.  Relapse (loco-regional or metastatic)  is  not  uncommon  in  this  disease.  Both  eribulin  and  capecitabine  are  effective  as  single  agent  in  relapsed  disease.  In  this  single-institutional  retrospective  study,  eribulin  and  capecitabine  have  been used  as  combination  chemotherapy regimen in patients  with  relapsed  carcinoma  breast.   Marerials and methods:       Patients  diagnosed  to  have  relapsed  carcinoma  of  breast,   who  were  ER and/or  PR positive,  Her-2/neu negative  or  triple negative  and  received  eribulin  alongwith capecitabine,  were  included  in  our  study.  Primary  objective  of  this  study  was  to  assess  response,  progression-free  survival (PFS)  and  overall  survival (OS).  Secondary objective  was  toxicity  assessment. Results:      48  patients  were  included  in  our  study.  Median  age  of  patients  was  56 years.  Thirty six (75%)  patients  had  ER and/or PR positive status  and  twelve (25%)  patients  had  ER/PR negative  status. Five (10.4%)  patients  achieved  complete  response (CR).  Thirty two (66.7%)  patients  achieved  partial  response (PR).  Disease  was  stable (SD)  in  nine (18.8%) patients.  Two (4.2%) patients  suffered  from  progressive  disease (PD).  Median   Progression-free survival (PFS)  was  10.15 months.  Mean  of  PFS  of  patients  was  10.72 (95% CI- 9.72-11.72)  months.  Median  overall survival (OS)  was  18.15 months.  Mean  of  overall  survival of  patients  was  19.56 (95% CI- 17.9-21.22) months.      Nineteen (39.6%)  and  three (6.2%)  patients  experienced  grade 2  and  grade 3  anemia  respectively.  Eighteen (37.5%)  and  two (4.2%)  patients  suffered  from  grade 2  and  grade 3 neutropenia  respectively.  One  patients  experienced  grade 2  thrombocytopenia.  Nineteen (39.6%)  patients  experienced  grade 2  diarrhoea.  One  patients  suffered  from  grade 3 diarrhoea.  Palmo-plantor  erythrodysesthesia  was  seen  in  eight (16.7%)  patients. Six (12.5%) patients  suffered  from  grade 2  neuropathy. Two (4.2%)  patients  experienced  grade 3 neuropathy.  Fatigue  was  seen  in  19 (39.6%)  patients. Conclusion:     Eribulin  alongwith  capectabine  can  be  used  in  patients  with  relapsed  carcinoma  breast,  in  whom  anthracycline  and  taxane  have  previously  been  used;  with response  rate  and  survival  better  than  either  single  agent  chemotherapy.  This  regimen  is  important  particularly  for  TNBC,  where  option  for  chemotherapy  is  limited. https://bccr.tums.ac.ir/index.php/bccrj/article/view/464